Cytek Biosciences, Inc. (CTKB) Misses Q3 EPS by 1c, Beats on Revenue

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Cytek Biosciences, Inc. (CTKB) Misses Q3 EPS by 1c, Beats on Revenue

Cytek Biosciences Reports Third Quarter 2025 Financial Results

November 5, 2025 4:06 PM EST

FREMONT, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (Cytek Biosciences or Cytek) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2025.

Recent Highlights

Total revenue for the third quarter of 2025 was $52.3 million, representing a 2% increase compared to the third quarter of 2024
Expanded to a total installed base of 3,456 Cytek instruments, adding 161 units in the third quarter of 2025Double-digit total revenue growth year-over-year in all regions, except EMEAWorldwide revenue from biotechnology, pharmaceutical and clinical research organization (CRO) customers grew 14%... More